Fig. 8.

Anastellin decreases the availability of the synergy site epitope in matrix fibronectin. (A) Microvessel cell monolayers were treated with 5 µM anastellin for 60 minutes, fixed, permeabilized and stained using a fibronectin-blocking antibody (HFN7.1) against the synergy site in the FnIII₉ module or an antibody (clone 568) that binds to the FnIII₈ module. Scale bar: 10 µm. (B) Total fluorescence was quantified using NIH ImageJ software. Data show the mean±s.e.m. (at least six fields of view, two independent experiments).